Results 11 to 20 of about 5,333 (223)

The Bioavailability of Xanthohumol in Humans and the Influence of Formulation and Dose: Randomized Controlled Trial Data. [PDF]

open access: yesMol Nutr Food Res
The effects of two different doses of micellar and native xanthohumol on plasma kinetics were investigated in 12 healthy men and women. Micellization significantly improved the bioavailability of xanthohumol. A subsequent placebo‐controlled study on the acute effects of xanthohumol on resting energy expenditure, blood pressure, and heart rate in 16 ...
Brehmer-Henkel S   +10 more
europepmc   +2 more sources

Microbial Conjugation Studies of Licochalcones and Xanthohumol [PDF]

open access: yesInternational Journal of Molecular Sciences, 2021
Microbial conjugation studies of licochalcones (1–4) and xanthohumol (5) were performed by using the fungi Mucor hiemalis and Absidia coerulea. As a result, one new glucosylated metabolite was produced by M. hiemalis whereas four new and three known sulfated metabolites were obtained by transformation with A. coerulea.
Fubo Han, Yina Xiao, Ik-Soo Lee
openaire   +2 more sources

Synthesis of xanthohumol and xanthohumol-d3 from naringenin

open access: yesRSC Advances, 2021
A six-step synthesis of xanthohumol and its d3-derivative from easily accessible naringenin is reported.
Joanna Andrusiak   +5 more
openaire   +3 more sources

Xanthohumol prevents atherosclerosis by reducing arterial cholesterol content via CETP and apolipoprotein E in CETP-transgenic mice. [PDF]

open access: yesPLoS ONE, 2012
BACKGROUND: Xanthohumol is expected to be a potent anti-atherosclerotic agent due to its inhibition of cholesteryl ester transfer protein (CETP). In this study, we hypothesized that xanthohumol prevents atherosclerosis in vivo and used CETP-transgenic ...
Hiroshi Hirata   +6 more
doaj   +1 more source

Inverse Molecular Docking Elucidating the Anticarcinogenic Potential of the Hop Natural Product Xanthohumol and Its Metabolites

open access: yesFoods, 2022
Natural products from plants exert a promising potential to act as antioxidants, antimicrobials, anti-inflammatory, and anticarcinogenic agents. Xanthohumol, a natural compound from hops, is indeed known for its anticarcinogenic properties.
Katarina Kores   +3 more
doaj   +1 more source

Exploration of isoxanthohumol bioconversion from spent hops into 8-prenylnaringenin using resting cells of Eubacterium limosum [PDF]

open access: yes, 2020
Hops is an almost unique source of the potent phytoestrogen 8-prenylnaringenin (8-PN). As hops contain only low levels of 8-PN, synthesis may be more attractive than extraction.
Bolca, Selin   +6 more
core   +2 more sources

Xanthohumol Inhibits the Growth of Keratin 18-Overexpressed Esophageal Squamous Cell Carcinoma in vitro and in vivo

open access: yesFrontiers in Cell and Developmental Biology, 2020
Esophageal squamous cell carcinoma (ESCC) is a leading cause of cancer-related death worldwide. Xanthohumol is a prenylated flavonoid isolated from hops.
Shuying Yin   +21 more
doaj   +1 more source

Bioactive Compounds Obtained from Polish “Marynka” Hop Variety Using Efficient Two-Step Supercritical Fluid Extraction and Comparison of Their Antibacterial, Cytotoxic, and Anti-Proliferative Activities In Vitro

open access: yesMolecules, 2021
Given the health-beneficial properties of compounds from hop, there is still a growing trend towards developing successful extraction methods with the highest yield and also receiving the products with high added value.
Katarzyna Klimek   +5 more
doaj   +1 more source

Xanthohumol-Enriched Beer Does Not Exert Antitumorigenic Effects on HeLa Cell Line In Vivo

open access: yesMolecules, 2023
Xanthohumol is a hop-derived flavonoid that has been widely examined for its health-protecting and antitumorigenic properties, but not yet in a natural beer matrix.
Anna Júlia Éliás   +6 more
doaj   +1 more source

Protective effects of Xanthohumol against diabetic nephropathy in a mouse model

open access: yesKidney & Blood Pressure Research, 2023
Introduction: Diabetic nephropathy (DN) is a long-term loss of renal function occurring in the diabetic patients, leading to 5 million deaths in 2015, and this number is dramatically growing annually.
Fenglin Li   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy